ROCHE/SYNTEX IS DIFFERENT TYPE OF DEAL THAN GENENTECH: SWISS COMPANY FACES TURNAROUND, COST-CUTTING; $5.3 BIL. OFFER CONSUMMATES FOUR-YEAR TORADOL AFFAIR